Navigation Links
Nautilus Neurosciences Announces New Patent Issued
Date:2/1/2012

BEDMINSTER, N.J., Feb. 1, 2012 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that United States Patent and Trademark Office has issued U.S. Patent 8,097,651 entitled "Diclofenac formulations and methods of use." This patent relates to methods and formulations for treating migraine. Additionally, methods are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. The patent provides additional protection for Cambia™, Nautilus' marketed product for the treatment of migraine through June 2026. This patent was licensed to Nautilus for Cambia™ in the North American markets by the Swiss company APR Applied Pharma Research, and is now listed in the FDA's Orange Book.

This coverage is in addition to that provided by U.S. Patent Nos. 7,759,394; 7,482,377; and 6,974,595.

About CAMBIA™

Nautilus' lead product, CAMBIA™, is a novel treatment for acute migraine in adults. CAMBIA is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Engineered using Dynamic Buffering Technology (DBT), CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. Designed to treat the underlying pathophysiology of migraine, Cambia reaches peak blood levels within 15 minutes and has been proven to provide equally as rapid relief in migraine. The FDA approval of CAMBIA was based on two Phase 3 placebo-controlled trials showing that CAMBIA was superior to placebo in all four FDA-mandated co-primary end points for migraine -- pain, nausea, photophobia and phonophobia. Both studies also showed that reduction in pain intensity was significantly greater in the CAMBIA group than in the placebo group as early as 15 minutes following treatment, and headache response rates were superi
'/>"/>

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
2. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
3. Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
4. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
5. Intellect Neurosciences, Inc. to Present at OneMedForum
6. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
7. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
8. Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimers Disease and Other Proteinopathies
9. Intellect Neurosciences Issues Letter to Shareholders
10. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
11. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)...  Elekta has CE marked the latest version (v5.10) ... enabling European clinics to deliver a sophisticated radiation therapy ... 3D planning, IMRT, VMAT and stereotactic planning – all ... Monaco ® v5.10 provides significant planning ... in 3D planning as well as the addition of ...
(Date:4/23/2015)... April 23, 2015  ResMed Inc. (NYSE: RMD ... 31, 2015.  Revenue for the quarter was $422.5 million, ... March 31, 2014 (a 13 percent increase on a ... increase of 1 percent compared to the quarter ended ... quarter were $0.64, an increase of 2 percent compared ...
(Date:4/23/2015)... April 23, 2015 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2015 on Thursday, April 30, 2015, after ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ... can be accessed through a link that is posted on ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... 5, 2011 Express Scripts contributed more than $226 ... economic analysis of the company,s data by a university ... The economic impact study, presented today to state economic ... support 2,665 direct and indirect jobs in the state. ...
... NeuroVasx announced today that the FDA ... Humanitarian Use Device (HDE) for the treatment of large, ... most difficult to treat.  The HDE allows for the ... the U.S. (Logo: http://photos.prnewswire.com/prnh/20110405/CG77724LOGO ) ...
Cached Medicine Technology:Express Scripts Injects $226 Million Into Arizona Economy, Study Finds 2NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System 2
(Date:4/26/2015)... Indiana (PRWEB) April 26, 2015 Indiana ... service provider announces that Brotherhood Mutual Insurance Company has ... Armstrong, Manager of Network Infrastructure at Brotherhood Mutual Insurance ... and the service reliability Brotherhood Mutual needed. ... diversity, and IFN worked with us to ensure we ...
(Date:4/26/2015)... FL (PRWEB) April 26, 2015 A ... pieces of medical equipment from hospitals, surgery centers and ... of equipment will be sold including radiology, surgery, endoscopy, ... live auction will take place Tuesday, April 28th starting ... Lauderdale warehouse located at 5025 North Hiatus Rd., Sunrise, ...
(Date:4/26/2015)... In an article published last month ... head-neck biomechanics occurring during the use of handheld electronic devices ... determine that use of a tablet increases mechanical demand on ... - more than when the neck is in a neutral ... but pointing out the potential hazards of overuse of mobile ...
(Date:4/26/2015)... MidSouth Pain Treatment Center has announced ... Treatment Center is a comprehensive pain management center including ... two ambulatory surgery centers in Germantown and Southaven, and ... , Dr. Michael Steuer , founder of MidSouth ... people, and when I discovered that I could make ...
(Date:4/25/2015)... California (PRWEB) April 26, 2015 Avid ... search for original 1965 Rolling Stones Greensboro Coliseum concert posters. ... was part of the Stone's Second American Tour. ... Globe Poster Company out of Baltimore, Maryland. This poster ... the northeast and southern cites. Globe uses garish lettering ...
Breaking Medicine News(10 mins):Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2
... Enjoying the eating process without focus on dietary restrictions ... according to researchers who have unveiled a new and ... Competence Model, also known as ecSatter, was created by ... of Secrets of Feeding a Healthy Family, Kelcy ...
... Significant Data Detailed at a Late-Breaking Presentation at ... ... 18 Iomai,Corporation (Nasdaq: IOMI ) today announced that travelers ... be sickened as compared with travelers who receive a placebo,according to ...
... (NYSE: AGP ) today announced that it ... and Medicare Services (CMS) to offer both,Medicare Advantage ... plans to address the specialized needs of seniors ... currently coordinates care for approximately 5,000,individuals through Medicare ...
... N.C., Sept. 18 Contact centers have been,transformed ... movement,that has reps selling while conducting ongoing customer ... skills are critical for,converting service reps to sales ... Practices, LLC. Ninety-eight percent of the 57 ...
... Researchers at the University of Pennsylvania School of ... Quality (AHRQ) have developed a framework to help ... challenges of implementing health information technology (HIT) by ... and quality. , As documented in a ...
... WASHINGTON, Sept. 18, 2007 -- A long-term study found ... patients with life-threatening diseases, such as leukemia and lymphoma, ... Further, males are likely to recover from these changes ... compromised. In addition, neither male nor female long-term cancer ...
Cached Medicine News:Health News:Nutrition model stresses positive experience of eating 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 3Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 4Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 5Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 2Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 3Health News:Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills 2Health News:Unanticipated consequences of health-care information technology 2Health News:Sexual function affected by stem cell transplant according to long-term study 2Health News:Sexual function affected by stem cell transplant according to long-term study 3Health News:Sexual function affected by stem cell transplant according to long-term study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: